Auris Medical: Rises as co starts clinical trial of nasal spray to treat allergic rhinitis

Altamira Therapeutics

29/01/2021 14:11

** U.S.-listed shares of Switzerland-based biotechnology co
Auris Medical Holding Ltd  EARS.O  rise 4.6% to $2.93 premarket
    ** Co says it is initiating a clinical trial of its
experimental drug-free nasal spray  AM-301 in the treatment of
allergic rhinitis  urn:newsml:reuters.com:*:nGNX99TpRP
    ** Allergic rhinitis or hay fever is caused by an allergic
response to outdoor or indoor allergens such as pollen and dust
mites
    ** Co says study participants to be administered a single
dose of AM-301 nasal spray or a comparator product prior to
controlled pollen exposure for four hours 
    ** Study results expected in Q2 2021; trial shall
demonstrate clinical non-inferiority of AM-301 to the comparator
product - Co
    ** Auris Medical is also testing AM-301 for use in
protection against COVID-19 and last month reported positive
results from its in-vitro study  urn:newsml:reuters.com:*:nL4N2IH3PO
    ** Stock up 6.9% YTD, as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))